Clinical Trials Logo

Filter by:
NCT ID: NCT03900468 Recruiting - Epilepsy Clinical Trials

Medtronic Deep Brain Stimulation (DBS) Therapy for Epilepsy Post-Approval Study (EPAS)

EPAS
Start date: March 5, 2020
Phase: N/A
Study type: Interventional

The purpose of this post-approval study is to further evaluate the long-term safety and effectiveness of Medtronic DBS therapy for epilepsy on seizure reduction in newly implanted participants through 3 years of follow-up.

NCT ID: NCT03899155 Recruiting - Cancer Clinical Trials

Pan Tumor Rollover Study

Start date: August 9, 2019
Phase: Phase 2
Study type: Interventional

Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.

NCT ID: NCT03899077 Recruiting - Cancer of Prostate Clinical Trials

Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP

SAVE
Start date: April 5, 2019
Phase: Phase 2
Study type: Interventional

This is a phase II randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy (ADT) with LHRH agonist or antagonist (arm A) versus anti-androgen therapy (AAT) with apalutamide 240mg daily (arm B) in hormone-naïve patients with biochemical progression after radical prostatectomy. All subjects will receive salvage radiotherapy as standard of care and will be randomly assigned in a 1:1 ratio to receive either 6 months of androgen-deprivation therapy (ADT) with LHRH agonist or antagonist through 6 monthly, two 3-monthly or one 6-monthly injections (control arm) or 6 28-day cycles of apalutamide 240mg daily (interventional arm). The study will include a screening phase, treatment phase, and a post-treatment phase. The primary objective of the trial is to compare sexual function between the 2 groups based on the Expanded Prostate cancer Index Composite (EPIC)-26 sexual domain scores at 9 months after start of hormonal treatment.

NCT ID: NCT03896113 Recruiting - Endometrium Cancer Clinical Trials

Neoadjuvant Celecoxib in Newly Diagnosed Patients With Endometrial Carcinoma

CELEBRIDO
Start date: November 13, 2019
Phase: Phase 2
Study type: Interventional

Indoleamine 2,3 dioxygenase 1 (IDO 1) is the major enzyme catabolising the Tryptophan outside the liver. It has been shown that its plays a important role in generating a immunosuppressive micro-environment in tumors. IDO expression has been shown by Hennequart et al. to be driven by Cyclooxygenase-2 (COX-2) expression. The investigator's team also shown that anti-COX2, celecoxib, can in a xenograft models of ovarian cancer decrease IDO1 expression and result in an infiltration of the tumor by T cells. The investigator proposed then to conduct a proof of concept study to evaluate the effect of pre-operative short administration of Celecoxib on IDO expression and Immune cells tumors infiltration, in patients with endometrial cancer. Indeed, this tumor type is well known to express frequently a high level of IDO.

NCT ID: NCT03888300 Recruiting - Clinical trials for Obstructive Pulmonary Disease

Measurement of Viscoelastic Properties of Bronchopulmonary Secretions.

VLM-2
Start date: August 1, 2019
Phase: N/A
Study type: Interventional

The study is experimental and aims to (a) compare the viscoelastic properties of bronchial secretions obtained in patients suffering from obstructive respiratory disease, and (b) to compare the viscoelastic properties of bronchial secretions obtained in patients before and after application of a respiratory physiotherapy or exercise as usually prescribed. After agreement, the sputum of the participants will be collected according to the method used in clinical routine.Experiments (collection and analysis of sputum) will be conducted at the Saint-Luc University Clinic.

NCT ID: NCT03888209 Recruiting - Stroke, Acute Clinical Trials

Transcranial Direct Current Stimulation (tDCS) Improves Functional Outcomes in Acute Stroke Patients

tDCS ASAP
Start date: March 31, 2019
Phase: N/A
Study type: Interventional

Acute stroke patient will undergo one month (20 sessions) of physical therapy and anodal tDCS. Patients will undergo functional outcomes measured at 48h post onset, 7,14,21,28 days, 3 and 6 months and one year post onset.

NCT ID: NCT03887156 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft

Predictor2
Start date: September 16, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

The aim is to validate an in vitro diagnosis medical device to predict grade II to IV aGVHD after a cell graft

NCT ID: NCT03883542 Recruiting - Clinical trials for Ovarian Neoplasm Epithelial

Sub-type Specific Genomic Mutations in sBOTs

Start date: January 2017
Phase:
Study type: Observational

The aim of this study is to identify different origin in carcinogenesis between serous borderline ovarian tumors presenting a. without implants, b. with non-invasive implants, c. with invasive implants and d. with micropapillary pattern. The presence of specific mutations could suggest for a more aggressive primary treatment if a higher risk of recurrence can be expected.

NCT ID: NCT03882151 Recruiting - Epilepsies, Partial Clinical Trials

Added Value of Automated Electrical Source Localization (EPILOG PreOp®) to Presurgical Evaluation of Refractory Epilepsy

EPILOG
Start date: January 15, 2019
Phase: N/A
Study type: Interventional

Drug resistant epilepsy is best managed by surgery. The goal of presurgical evalution is to correctly identify the epileptogenic zone, defined by the extent of cortical tissue that needs to be removed is order to achieve seizure freedom. When no causative lesion is identified, careful study of interictal activity is mandatory. Complementary analysis methods exist, designed to identify the source of electrical activity recorded with surface electro-encephalogram. While results are interesting in retrospective studies, the real clinical added value needs to be demonstrated with prospective studies. The company Epilog (Epilog, Ghent, Belgium) offers, with EPILOG PreOp®, a long-term EEG analysis to automatically detect epileptiform activity, combined with an estimation of the electrical source localization using a sLORETA inverse solution model. We will propose the EPILOG PreOp analysis to refractory epileptic patients with non-contributive cerebral imaging, under presurgical evaluation. By comparing the therapeutic decision with and without knowledge of the results of EPILOG PreOp®, we will establish the added clinical value of EPILOG PreOp®.

NCT ID: NCT03881527 Recruiting - Clinical trials for Aortic Valve Stenosis

Nitinol Circular Blade

NCB
Start date: October 2015
Phase: N/A
Study type: Interventional

The Nitinol Circular Blade (NCB) is indicated for use in patients with symptomatic aortic stenosis requiring aortic valve replacement, who are going to be operated by conventional sternotomy with native valve resection and replacement by a prosthetic aortic valve. The resection of the diseased leaflets will be performed by the NCB rather than conventional surgical blade.